Ostalo
UPDATE ON GUIDELINES FOR PHARMACOLOGICAL TREATMENT OF MULTIPLE SCLEROSIS BY THE CROATIAN SOCIETY FOR NEUROVASCULAR DISORDERS OF THE CROATIAN MEDICAL ASSOCIATION AND CROATIAN SOCIETY OF NEUROIMMUNOLOGY AND NEUROGENETICS
VANJA BAŠIĆ KES
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Sveučilište u Zagrebu, Stomatološki fakultet, Zagreb, Hrvatska
MILJENKA JELENA JURAŠIĆ
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Hrvatska
IRIS ZAVOREO
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Hrvatska
MARIJANA LISAK
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Sveučilište u Zagrebu, Stomatološki fakultet, Zagreb, Hrvatska
SILVA SOLDO BUTKOVIĆ
; Sveučilište Josipa Jurja Strossmayera u Osijek, Medicinski fakultet, Osijek, Klinički bolnički centar Osijek, Klinika za neurologiju, Osijek, Hrvatska
MARINA TITLIĆ
; Klinički bolnički centar Split, Klinika za neurologiju, Split, Hrvatska
MERI MATIJACA
; Klinički bolnički centar Split, Klinika za neurologiju, Split, Hrvatska
INES LAZIBAT
; Sveučilište Josipa Jurja Strossmayera u Osijek, Medicinski fakultet, Osijek, Klinička bolnica Dubrava, Klinika za neurologiju, Zagreb, Hrvatska
DAVOR JANČULJAK
; Sveučilište Josipa Jurja Strossmayera u Osijek, Medicinski fakultet, Osijek, Klinički bolnički centar Osijek, Klinika za neurologiju, Osijek, Hrvatska
MARIO HABEK
; Klinički bolnički centar Zagreb, Klinika za neurologiju, Zagreb, Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
MARIJA BOŠNJAK PAŠIĆ
; Sveučilište Josipa Jurja Strossmayera u Osijek, Medicinski fakultet, Osijek, Klinički bolnički centar Zagreb, Klinika za neurologiju, Zagreb, Hrvatska
IVANA ZADRO
; Klinički bolnički centar Zagreb, Klinika za neurologiju, Zagreb, Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
INGRID ŠKARPA PRPIĆ
; Klinički bolnički centar Rijeka, Klinika za neurologiju, Rijeka, Hrvatska
IVANA HUSTIĆ
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Hrvatska
NEVENA GRBIĆ
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Hrvatska
IVANA KOBASIĆ
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Zagreb, Hrvatska
TEA MIROŠEVIĆ ZUBONJA
; Klinički bolnički centar Osijek, Klinika za neurologiju, Osijek, Hrvatska
ANITA MARČINKO
; Klinička bolnica Sveti Duh, Klinika za neurologiju, Zagreb, Hrvatska
ANTON VLADIĆ
; Sveučilište Josipa Jurja Strossmayera u Osijek, Medicinski fakultet, Osijek, Klinička bolnica Sveti Duh, Klinika za neurologiju Zagreb, Hrvatska
DOLORES JANKO LABINEC
; Opća bolnica Pula, Odjel neurologije, Pula, Hrvatska
TIHANA GRŽINČIĆ
; Opća bolnica Bjelovar, Odjel neurologije,Bjelovar, Hrvatska
BISERKA KOVAČ
; Opća bolnica Vukovar, Odjel neurologije,Vukovar, Hrvatska
ANKA ALEKSIĆ SHIHABI
; Opća bolnica Šibenik, Odjel neurologije, Šibenik, Hrvatska
VIDA DEMARIN
; Hrvatska akademija znanosti i umjetnosti, Zagreb, Hrvatska
Sažetak
Multiple sclerosis (MS) affects the central nervous system (CNS) and presents by numerous symptoms from different CNS functional systems. As the number of available treatments has increased in recent years, the need has emerged for continuous evaluation on MS diagnosis and treatment based on evidence-based medicine. This implies the need for continuous renewal of national and international guidelines, in our case, based on the regional guidelines of the European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology (EAN) with the aim of providing the best medical therapy for each patient, based on an individualized approach. These new guidelines are based on the recently updated EAN recommendations that have been derived as the result of exhaustive literature research as of December 2016. Given the risk of system error, the quality of evidence for each outcome has been subdivided into four categories, as follows: very high, high, low and very low. Given the quality of evidence and the risk and benefit ratio, the recommendations are accompanied by strong and weak strength. The research was focused on several key issues, including treatment effectiveness, response to therapy applied, strategy for recognizing appropriate response and safety, and therapeutic strategy for MS treatment during pregnancy. The guidelines cover all medicines that modify the course of the disease and are approved by the European Medicines Agency. Patients with clinically isolated syndrome that do not meet diagnostic criteria for clinically definitive MS have been assigned to special groups while patients with proven MS are divided into different clinical subtypes of MS in accordance with valid diagnostic guidelines.
Ključne riječi
multiple sclerosis; disease-modifying treatment; guidelines
Hrčak ID:
208635
URI
Datum izdavanja:
16.11.2018.
Posjeta: 2.269 *